Literature DB >> 11093809

Variations in proteasome subunit composition and enzymatic activity in B-lymphoma lines and normal B cells.

T Frisan1, V Levitsky, M G Masucci.   

Abstract

We investigated the expression of interferon gamma (IFN-gamma)-regulated subunits and the enzymatic activity of proteasomes purified from tumor-derived and normal B lymphocytes representing different stages of B-cell activation/differentiation. The catalytic beta subunits (Lmp2 and Lmp7) and the regulatory subunits (PA28alpha and PA28beta) were expressed at equally high levels in Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs), freshly isolated B-chronic lymphocytic leukemia (B-CLL) cells and normal CD23(-) B lymphocytes. Lmp2 and Lmp7 were selectively down-regulated in germinal center cell-derived Burkitt's lymphoma (BL) and Hodgkin's lymphoma (HD) cell lines. There was a direct correlation between the expression of Lmp2/7 and the chymotrypsin and trypsin-like activities in proteasomes purified from LCLs, BLs and CLL cells, whereas 5 HD cell lines expressing B or T-cell markers exhibited a variable pattern of subunit expression and enzymatic activity. Poor hydrolysis of the fluorogenic substrates by proteasomes from BL cells correlated with a distinct pattern of cleavage of a reference 50mer peptide, production of different sets of degradation products and significantly reduced recovery of a known cytotoxic T-lymphocyte (CTL) target epitope. The enzymatic activity of proteasomes from normal CD23(-) "resting" B lymphocytes resembled that of BL cells in spite of high Lmp2/7 expression. This pattern was not reversed by treatment with the B-cell mitogen, lipopolysaccharide (LPS). The results suggest that different stages of B-cell activation/differentiation are associated with distinct profiles of IFN-gamma-regulated subunit composition and enzymatic activity of the proteasome. This may have important implications for the analysis and manipulation of tumor-specific immune responses. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093809     DOI: 10.1002/1097-0215(20001215)88:6<881::aid-ijc7>3.0.co;2-d

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

Review 1.  Emerging roles of immunoproteasomes beyond MHC class I antigen processing.

Authors:  Frédéric Ebstein; Peter-Michael Kloetzel; Elke Krüger; Ulrike Seifert
Journal:  Cell Mol Life Sci       Date:  2012-03-02       Impact factor: 9.261

2.  Functional module search in protein networks based on semantic similarity improves the analysis of proteomics data.

Authors:  Desislava Boyanova; Santosh Nilla; Gunnar W Klau; Thomas Dandekar; Tobias Müller; Marcus Dittrich
Journal:  Mol Cell Proteomics       Date:  2014-05-07       Impact factor: 5.911

3.  Regulation of BOB.1/OBF.1 stability by SIAH.

Authors:  J Boehm; Y He; A Greiner; L Staudt; T Wirth
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

Review 4.  The role of the proteasome in the generation of MHC class I ligands and immune responses.

Authors:  E J A M Sijts; P M Kloetzel
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

5.  The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.

Authors:  X Papanikolaou; D Alapat; A Rosenthal; C Stein; J Epstein; R Owens; S Yaccoby; S Johnson; C Bailey; C Heuck; E Tian; A Joiner; F van Rhee; R Khan; M Zangari; Y Jethava; S Waheed; F Davies; G Morgan; B Barlogie
Journal:  Leukemia       Date:  2015-03-10       Impact factor: 11.528

Review 6.  Lymphoma: immune evasion strategies.

Authors:  Ranjan Upadhyay; Linda Hammerich; Paul Peng; Brian Brown; Miriam Merad; Joshua D Brody
Journal:  Cancers (Basel)       Date:  2015-04-30       Impact factor: 6.639

Review 7.  The immunoproteasome and viral infection: a complex regulator of inflammation.

Authors:  Mary K McCarthy; Jason B Weinberg
Journal:  Front Microbiol       Date:  2015-01-29       Impact factor: 5.640

8.  Multicolor monitoring of the proteasome's catalytic signature.

Authors:  Melanie A Priestman; Qunzhao Wang; Finith E Jernigan; Ruma Chowdhury; Marion Schmidt; David S Lawrence
Journal:  ACS Chem Biol       Date:  2014-11-07       Impact factor: 5.100

9.  Selective cytotoxicity of amidinopiperidine based compounds towards Burkitt's lymphoma cells involves proteasome inhibition.

Authors:  Martina Gobec; Ales Obreza; Matevz Prijatelj; Boris Brus; Stanislav Gobec; Irena Mlinaric-Rascan
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

Review 10.  New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells.

Authors:  Hiroaki Kimura; Patrizio Caturegli; Masafumi Takahashi; Koichi Suzuki
Journal:  J Immunol Res       Date:  2015-10-08       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.